Homoharringtonine Promotes Heart Allograft Acceptance by Enhancing Regulatory T Cells Induction in a Mouse Model

Overview

Journal Chin Med J (Engl)

Specialty General Medicine

Date 2023 Nov 14

PMID 37962205

Authors

Xia Qiu

Hedong Zhang

Zhouqi Tang

Yuxi Fan

Wenjia Yuan

Chen Feng

Chao Chen

Pengcheng Cui

Yan Cui

Zhongquan Qi

Tengfang Li

Yuexing Zhu

Liming Xie

Fenghua Peng

Tuo Deng

Xin Jiang

Longkai Peng

Helong Dai

Affiliations

Soon will be listed here.

Abstract

Background: Homoharringtonine (HHT) is an effective anti-inflammatory, anti-viral, and anti-tumor protein synthesis inhibitor that has been applied clinically. Here, we explored the therapeutic effects of HHT in a mouse heart transplant model.

Methods: Healthy C57BL/6 mice were used to observe the toxicity of HHT in the liver, kidney, and hematology. A mouse heart transplantation model was constructed, and the potential mechanism of HHT prolonging allograft survival was evaluated using Kaplan-Meier analysis, immunostaining, and bulk RNA sequencing analysis. The HHT-T cell crosstalk was modeled ex vivo to further verify the molecular mechanism of HHT-induced regulatory T cells (Tregs) differentiation.

Results: HHT inhibited the activation and proliferation of T cells and promoted their apoptosis ex vivo . Treatment of 0.5 mg/kg HHT for 10 days significantly prolonged the mean graft survival time of the allografts from 7 days to 48 days ( P <0.001) without non-immune toxicity. The allografts had long-term survival after continuous HHT treatment for 28 days. HHT significantly reduced lymphocyte infiltration in the graft, and interferon-γ-secreting CD4 + and CD8 + T cells in the spleen ( P <0.01). HHT significantly increased the number of peripheral Tregs (about 20%, P <0.001) and serum interleukin (IL)-10 levels. HHT downregulated the expression of T cell receptor (TCR) signaling pathway-related genes ( CD4 , H2-Eb1 , TRAT1 , and CD74 ) and upregulated the expression of IL-10 and transforming growth factor (TGF)-β pathway-related genes and Treg signature genes ( CTLA4 , Foxp3 , CD74 , and ICOS ). HHT increased CD4 + Foxp3 + cells and Foxp3 expression ex vivo , and it enhanced the inhibitory function of inducible Tregs.

Conclusions: HHT promotes Treg cell differentiation and enhances Treg suppressive function by attenuating the TCR signaling pathway and upregulating the expression of Treg signature genes and IL-10 levels, thereby promoting mouse heart allograft acceptance. These findings may have therapeutic implications for organ transplant recipients, particularly those with viral infections and malignancies, which require a more suitable anti-rejection medication.

Citing Articles

Comment on Homoharringtonine promotes heart allograft acceptance by enhancing regulatory T cells induction in a mouse model.

Zhang Y, Zhang H Chin Med J (Engl). 2025; .

PMID: 39863570 PMC: 11882293. DOI: 10.1097/CM9.0000000000003492.

References

Mi R, Zhao J, Chen L, Liu J, Wei X . Efficacy and Safety of Homoharringtonine for the Treatment of Acute Myeloid Leukemia: A Meta-analysis. Clin Lymphoma Myeloma Leuk. 2021; 21(10):e752-e767. DOI: 10.1016/j.clml.2021.06.002. View

Garreau de Loubresse N, Prokhorova I, Holtkamp W, Rodnina M, Yusupova G, Yusupov M . Structural basis for the inhibition of the eukaryotic ribosome. Nature. 2014; 513(7519):517-22. DOI: 10.1038/nature13737. View

Yao Y, Yang Y, Guo W, Xu L, You M, Zhang Y . METTL3-dependent mA modification programs T follicular helper cell differentiation. Nat Commun. 2021; 12(1):1333. PMC: 7910450. DOI: 10.1038/s41467-021-21594-6. View

Chen X, Du Y, Huang Z . CD4+CD25+ Treg derived from hepatocellular carcinoma mice inhibits tumor immunity. Immunol Lett. 2012; 148(1):83-9. DOI: 10.1016/j.imlet.2012.09.002. View

Choquette M, Goebel J, Campbell K . Nonimmune complications after transplantation. Pediatr Clin North Am. 2010; 57(2):505-21, table of contents. DOI: 10.1016/j.pcl.2010.01.008. View

Roberts M, Fishman J . Immunosuppressive Agents and Infectious Risk in Transplantation: Managing the "Net State of Immunosuppression". Clin Infect Dis. 2020; 73(7):e1302-e1317. PMC: 8561260. DOI: 10.1093/cid/ciaa1189. View

Gurel G, Blaha G, Moore P, Steitz T . U2504 determines the species specificity of the A-site cleft antibiotics: the structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome. J Mol Biol. 2009; 389(1):146-56. PMC: 2682339. DOI: 10.1016/j.jmb.2009.04.005. View

Kantarjian H, Talpaz M, Santini V, Murgo A, Cheson B, OBrien S . Homoharringtonine: history, current research, and future direction. Cancer. 2001; 92(6):1591-605. DOI: 10.1002/1097-0142(20010915)92:6<1591::aid-cncr1485>3.0.co;2-u. View

Liu J, Shi L, Huang W, Zheng Z, Huang X, Su Y . Homoharringtonine Attenuates Dextran Sulfate Sodium-Induced Colitis by Inhibiting NF-B Signaling. Mediators Inflamm. 2022; 2022:3441357. PMC: 9536985. DOI: 10.1155/2022/3441357. View

10.

Gong M, Li S, Xie Y, Zhao F, Shao J, Zhang Y . Inhibitory effects of homoharringtonine on foot and mouth disease virus in vitro. J Med Virol. 2019; 91(9):1595-1601. PMC: 7166808. DOI: 10.1002/jmv.25494. View

11.

Powell R, Weisleder D, Smith Jr C, Rohwedder W . Structures of harringtonine, isoharringtonine, and homoharringtonine. Tetrahedron Lett. 1970; (11):815-8. DOI: 10.1016/s0040-4039(01)97839-6. View

12.

Kantarjian H, OBrien S, Cortes J . Homoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approval. Clin Lymphoma Myeloma Leuk. 2013; 13(5):530-3. PMC: 3775965. DOI: 10.1016/j.clml.2013.03.017. View

13.

Zhang W, Lu Y, Zhen T, Chen X, Zhang M, Liu P . Homoharringtonine synergy with oridonin in treatment of t(8; 21) acute myeloid leukemia. Front Med. 2018; 13(3):388-397. DOI: 10.1007/s11684-018-0624-1. View

14.

Zheng S, Chen Y, Wang Z, Che Y, Wu Q, Yuan S . Combination of matrine and tacrolimus alleviates acute rejection in murine heart transplantation by inhibiting DCs maturation through ROS/ERK/NF-κB pathway. Int Immunopharmacol. 2021; 101(Pt B):108218. DOI: 10.1016/j.intimp.2021.108218. View

15.

Lindqvist L, Vikstrom I, Chambers J, McArthur K, Ann Anderson M, Henley K . Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor. Cell Death Dis. 2012; 3:e409. PMC: 3481137. DOI: 10.1038/cddis.2012.149. View

16.

Badovinac V, Tvinnereim A, Harty J . Regulation of antigen-specific CD8+ T cell homeostasis by perforin and interferon-gamma. Science. 2000; 290(5495):1354-8. DOI: 10.1126/science.290.5495.1354. View

17.

Howard T, Oberlick E, Rees M, Arnoff T, Pham M, Brenan L . Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine. Clin Cancer Res. 2020; 26(18):4995-5006. PMC: 7501142. DOI: 10.1158/1078-0432.CCR-19-2717. View

18.

Robert F, Mills J, Agenor A, Wang D, DiMarco S, Cencic R . Targeting protein synthesis in a Myc/mTOR-driven model of anorexia-cachexia syndrome delays its onset and prolongs survival. Cancer Res. 2011; 72(3):747-56. DOI: 10.1158/0008-5472.CAN-11-2739. View

19.

Tibbitt C, Stark J, Martens L, Ma J, Mold J, Deswarte K . Single-Cell RNA Sequencing of the T Helper Cell Response to House Dust Mites Defines a Distinct Gene Expression Signature in Airway Th2 Cells. Immunity. 2019; 51(1):169-184.e5. DOI: 10.1016/j.immuni.2019.05.014. View

20.

Au E, Wong G, Chapman J . Cancer in kidney transplant recipients. Nat Rev Nephrol. 2018; 14(8):508-520. DOI: 10.1038/s41581-018-0022-6. View